To dissolve X-ray negative cholesterol gallstones no larger than 15 mm in diameter in patients with a functioning gallbladder, despite the presence of gallstone (s) in it. For the treatment of biliary reflux gastritis. For symptomatic treatment of primary biliary cirrhosis (PBC) in the absence of decompensated liver cirrhosis. For the treatment of hepatobiliary disorders in cystic fibrosis in children aged 6 to 18 yEars and Nose.
Composition and form of release
Ursofalk is produced in capsules and suspensions for oral administration. The active substance is ursodeoxycholic acid.
Ursofalk is prescribed to dissolve cholesterol gallstones in the gallbladder. It is also used in the treatment of biliary reflux gastritis and primary biliary cirrhosis (if there are no signs of decompensation in the work of this organ). The drug is prescribed in the composition of complex therapy for chronic gastritis of various etiology, primary sclerosing cholangitis, cystic fibrosis, non-alcoholic steatohepatitis, biliary dyskinesia and toxic alcoholic liver damage.
Ursofalk is not prescribed if, during an X-ray examination, stones in the gallbladder with a high calcium content, a non-functioning gallbladder, acute inflammatory lesion of the gallbladder, as well as its ducts and intestines were found. It is contraindicated in case of decompensated cirrhosis of the liver, severe disorders in the functioning of the kidneys, liver and pancreas. Ursofalk is not prescribed for intolerance to usodeoxycholic acid, as well as for women at the stage of pregnancy and lactation.
Application during pregnancy and lactation
Ursofalk is contraindicated in pregnant and lactating women.
Method of administration and dosage
Ursofalk capsules and suspensions are intended for oral administration. If the patient was prescribed a single dose of the drug, then it is carried out in the evening. The capsules are swallowed whole, without chewing and drinking a sufficient amount of liquid. If the patient has difficulty swallowing capsules, then the drug is prescribed in the form of a suspension.
The doctor selects the duration of therapy and the dose of Ursofalk individually, taking into account the severity of the disease and the severity of the symptoms. In the treatment of acute and chronic liver diseases and cholelithiasis, the drug is prescribed at 10 or 15 mg per kg of the patient’s body weight. The duration of treatment is from 6 months to 2 years. During drug therapy, it is unacceptable to take breaks in treatment. If after 12 months of treatment of gallstone disease there is no decrease in calculi, then the drug is stopped.
In the treatment of biliary reflux gastritis or reflux esophagitis, the drug is taken at 250 mg 1 time per day, preferably in the evening. The duration of therapy is from 10 to 14 days.
In the treatment of biliary cirrhosis or sclerosing cholangitis, the drug is 10 or 15 mg per kg of body weight per day. If necessary, the daily dose can be increased to 20 mg per kg of body weight. The duration of treatment is from 6 months to 2 years.
In the treatment of toxic liver damage or acute alcohol poisoning, the drug is taken at 10 or 15 mg per kg of body weight. Duration of treatment is from 6 to 12 months.
At the moment, no cases of Ursofalk overdose have been officially recorded.
Side effects are very rare when taking Ursofalk. In patients with hypersensitivity to the drug, there is the development of pain in the epigastric region, calcification of stones in the gallbladder. In addition, some patients have mushy stools and allergic reactions.
Storage conditions and periods
Ursofalk must be stored in a cool place, out of the reach of children and protected from light. The term of storage of the drug in capsules is 5 years.